Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (Diluted Average) (2019 - 2025)

Aclaris Therapeutics (ACRS) has 7 years of Shares Outstanding (Diluted Average) data on record, last reported at $122.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 58.56% year-over-year to $122.6 million; the TTM value through Dec 2025 reached $122.6 million, up 58.56%, while the annual FY2025 figure was $122.6 million, 58.56% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $122.6 million in Q4 2025 per ACRS's latest filing, roughly flat from $122.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $122.6 million in Q4 2025 and bottomed at $50.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $76.3 million, with a median of $69.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 0.62% in 2024, then skyrocketed 72.2% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $56.7 million in 2021, then grew by 14.95% to $65.2 million in 2022, then increased by 7.05% to $69.8 million in 2023, then increased by 10.73% to $77.3 million in 2024, then surged by 58.56% to $122.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $122.6 million in Q4 2025, $122.5 million in Q3 2025, and $122.5 million in Q2 2025.